In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.
about
Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional studyIn vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondiiActivities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophagesSynergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosisSynergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in miceClinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials GroupIn vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytesInterference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?Azithromycin inhibition of intracellular Legionella micdadeiThe role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.Short-course treatment of sinusitis and other upper respiratory tract infections with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group.Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group.Intravenous azithromycin.Resolution of localized chronic periodontitis associated with longstanding calculus depositsAzithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosisPopulation pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults.Postanitbiotic and sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli.Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia.Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.Localization of azithromycin in Toxoplasma gondii-infected cellsIntracellular activity of azithromycin against bacterial enteric pathogens.Pharmacokinetics of spiramycin in the rhesus monkey: transplacental passage and distribution in tissue in the fetus.In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydiaIntracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid.Pilot study of azithromycin in the treatment of genital donovanosis.Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young childrenTulathromycin exerts proresolving effects in bovine neutrophils by inhibiting phospholipases and altering leukotriene B4, prostaglandin E2, and lipoxin A4 productionDistribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients.Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrationsQuinupristin-dalfopristin: an overview.Chlamydia trachomatis genitourinary infections: laboratory diagnosis and therapeutic aspects. Evaluation of in vitro and in vivo effectiveness of azithromycin.Discovery and development of new antimicrobial agents.The macrolides.Therapy with macrolides in patients with cystic fibrosis.Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.In vivo efficacy of azithromycin in treatment of systemic infection and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin GActivity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumoniaDistribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.
P2860
Q21195368-6A8816EA-5E4D-4994-8183-E19D69A9E973Q28321674-DDA1B0C3-C94B-425F-B879-D60B7B0EA3BDQ28321761-313B86C8-6FA0-4A36-9F1A-94D43A1793AAQ28326714-88FF5633-C269-4EC9-9A86-76D17043354CQ28343091-65DE964B-0201-484E-AB84-CE71ECFB9728Q28344357-AB9E4AB8-4097-4C55-9182-E4CF19A88BF1Q30311321-9627C8C8-019F-4DF0-9442-E06456482E37Q30327329-12836114-B157-4F3C-B1D2-CC9BB3C19290Q30451684-982D4F85-1A58-4BD5-A356-83E2E9F4D1EDQ30577239-7BFDBB30-FA68-4B69-9C25-535E824FC766Q33239595-0FE3B414-77FA-4CEE-989A-295D0EE78C25Q33239597-40A63622-52A3-4BCF-A079-F72F478076ECQ33543121-79AAF261-5AB9-4942-9EDE-7AE511C69954Q33634494-3F3AE67E-5DA7-439A-A6FC-5923D15DCD38Q33640512-140DB8B0-BB7D-4CC5-A1AF-902EB29A8145Q33689718-3ECBFD45-8178-4D62-BF53-8BC10EB485CCQ33690065-66E4DC3C-C533-47EA-AB2E-83A6D66DFDDDQ33743363-F82B5B94-72E4-4061-A9D5-BD71AF7144F5Q33748466-5B3C0D4D-27F2-47CA-8D6B-07A3DAFD9637Q33755229-DCF087B4-0BD9-4E06-B698-3F03FAC55333Q33757644-98E22EE4-9553-4A4A-AE5D-FB713BA4BA58Q33757694-59AB0F5F-BFE2-44EE-BB88-B3CC6EFBC4C2Q33760662-F6990FC0-C864-4D80-B407-1AA337376FD9Q33761758-82B3EB10-8E04-4112-B428-DD26F74369D6Q33935897-FB841FCD-E4E6-4FCF-8A55-37251C2F8448Q33975933-6CB2B8CA-B97C-403D-8382-43DD2DA1094DQ33978422-300740F0-754D-4A92-9CD8-FB28D0302E63Q34058334-B37D674A-BA70-4925-AD9D-947356A035D8Q34106668-7C853BB9-2E7F-468B-B7DF-859C5DF88362Q34109849-3E102007-C2F0-4D2E-9D1C-5468665D3A74Q34113774-ADB2830D-0A2C-4E82-BAC9-FBA9036C43F2Q34316767-DEB91A96-80ED-4A95-B39B-7210D59247D0Q34371891-98049305-DDA4-45F7-9654-28BFA6908AA3Q34519125-D03CB3A1-B90A-407C-9D93-F9F8493FB97DQ34523880-B5DD703A-ADE4-4D2F-BE05-CDB6A55286F6Q35078545-B3E05214-9DE7-49E7-AE57-A099973B1E98Q35111440-E2B3302E-400A-4F99-AC2C-E316582EFAE9Q35118043-E670B546-5617-4932-A4F2-401A5FE55042Q35122254-A14465A1-E413-4E38-9A01-32933951E44FQ35123496-B212FFF9-BAA0-484F-9649-813BC7862FEA
P2860
In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
In vitro and in vivo uptake of ...... release at sites of infection.
@en
In vitro and in vivo uptake of ...... release at sites of infection.
@nl
type
label
In vitro and in vivo uptake of ...... release at sites of infection.
@en
In vitro and in vivo uptake of ...... release at sites of infection.
@nl
prefLabel
In vitro and in vivo uptake of ...... release at sites of infection.
@en
In vitro and in vivo uptake of ...... release at sites of infection.
@nl
P2093
P2860
P356
P1476
In vitro and in vivo uptake of ...... release at sites of infection.
@en
P2093
Isaacson RE
Newborg MF
P2860
P304
P356
10.1128/AAC.33.3.277
P407
P577
1989-03-01T00:00:00Z